Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer

Model scores of the 29,894 trials active now.

Model score 40% for any early termination, 21% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (851 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-10-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: cell lunglung cancersmall cellnon smallstage
  Phrases that lowered it: participantantiretroviralfactorindividualsadvanced
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 1/2 (raises risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Sponsor's past termination rate: 8.9% (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 23.8% (raises risk) · Drug's FDA history
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 123 (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 40 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Maximum age: not given (raises risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Number of arms: 3 (lowers risk) · Design
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports before start: 18889 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Immunotherapy With or Without SBRT in Patients With Stage IV Non-small Cell Lung Cancer NCT03867175 · started 2019 · scored riskier than 99% of active trials completed
• Stereotactic Body Radiation Therapy for Inoperable Locally-advanced Non-small Cell Lung Cancer NCT01899989 · started 2013 · scored riskier than 93% of active trials completed
• Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial NCT02045446 · started 2014 · scored riskier than 99% of active trials completed
• Combined CFRT and SABR in Stage II and III NSCLC With Peripheral Tumors Smaller Than 5 cm. NCT01933568 · started 2013 · scored riskier than 98% of active trials completed
• Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery NCT02262325 · started 2015 · scored riskier than 95% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.